Specific question about can we talk about how slow that I have not seen answered clearly anywhere:

Does timing matter?

Context: I am week 4 on 0.5mg sema. My provider said one thing but I have read conflicting info online.

Would appreciate hearing from people with direct experience, not just theoretical answers.

KarenAZ_mom said:

Can we talk about how SLOW the FDA is

Gonna push back on this one. Can we talk about how SLOW the FDA is not that straightforward in my experience. I have been on this for 18 months and the reality is messier than the trials suggest.

Don't get me wrong — the medication works. But adherence is harder than people admit. We should be honest about that.

KarenAZ_mom said:

Can we talk about how SLOW the FDA is

This is exactly right. KarenAZ_mom articulated what I have been trying to explain to my friends for months. The Can we talk about how aspect is what made the difference for me.

Clinical perspective on Can we talk about how SLOW the FDA is:

I have managed ~150 patients on GLP-1 therapy and this topic comes up frequently. What the data shows — and what I see in practice — is that the medication works best as part of a comprehensive approach.

For this specific question, I would recommend: getting comprehensive baseline labs first.

andrew_nyc said:

KarenAZ_mom articulated what I have been trying to explain to my friends for months

I respect andrew_nyc perspective but I think this oversimplifies things a bit. Re: Can we talk about how SLOW the — the subgroup analyses show meaningful heterogeneity.

I am not saying andrew_nyc wrong entirely — just that the picture is more nuanced than a blanket statement. The SURMOUNT data specifically shows baseline BMI-dependent responses.